Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma

Fable Zustovich, Giuseppe Lombardi, Davide Pastorelli, Patrizia Farina, Massimo dal Bianco, Luca de Zorzi, Maurizia Dalla Palma, Ornella Nicoletto, Vittorina Zagonel

Research output: Contribution to journalArticlepeer-review


Renal cell carcinoma (RCC) is a common malignancy worldwide with approximately 95,000 new cases per year and ranks as the sixth cause of cancer deaths. Until recently, the slightly active and very toxic cytokines were available for patients with advanced RCC. Advances have been made in understanding the molecular biology of renal cancer. The introduction of targeted agents has led to promising possibilities for treating these highly vascularized tumors. Angiogenesis inhibition is likely to represent the main potential therapeutic target. Sorafenib is an oral multikinase inhibitor with activity against tyrosine kinase receptors that are responsible for blood vessel development and has shown to be active in treating advanced RCC. In this review, we summarize the pharmacology, mode of action, pharmacokinetics, and safety of sorafenib use in therapy for advanced RCC.

Original languageEnglish
Pages (from-to)69-82
Number of pages14
JournalOpen Access Journal of Urology
Issue number1
Publication statusPublished - 2011


  • Angiogenesis
  • Pharmacokinetics
  • Sorafenib

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma'. Together they form a unique fingerprint.

Cite this